Key objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF-α, in the blood
MYMD-1 is designed to become the first and only FDA-approved therapeutic solution for delaying aging and prolonging lifespan
MYMD-1’s primary purpose is to slow the aging process and extend human lifespan, but it is also showing promise as a potential treatment for COVID-19-related complications, and as an anti-fibrotic and anti-prolific therapeutic. Because it can cross the blood-brain barrier, MYMD-1 is also positioned to be a possible treatment for multiple sclerosis and other brain-related disorders.
In addition to the upcoming Phase 2 aging trial, MyMD previously announced that it intends to initiate a Phase 2 trial of MYMD-1 as a therapy for COVID-19-associated depression and cytokine elevation in the fourth quarter of 2021, with initial trial data expected in the first quarter of 2022.
https://finance.yahoo.com/news/mymd-pharmaceuticals-announces-fourth-quarter-140000209.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.